Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Items 201–300 of 1,010
Hu, W., Song, M., Wang, C., Guo, Z., Li, Y., & Wang, D. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.117 · Cited by 47
Ghasemi-Tarie, R., Kiasalari, Z., Fakour, M., Khorasani, M., Keshtkar, S., Baluchnejadmojarad, T., & Roghani, M. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00949-y · Cited by 46
“Although multiple cholinesterase inhibitors have been approved for symptomatic relief of AD (Breijyeh and Karaman 2020), however, there is no definite therapy for AD and hence finding new effective drugs targeting downstream processes involved in AD pathogenesis including neuroinflammation and…”
BackgroundAlzheimer’s Disease: A Systems View Provides a Unifying Explanation of Its Development
Grobler, C., van Tongeren, M., Gettemans, J., Kell, D. B., & Pretorius, E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220720 · Cited by 51
“ThisdrughasalowaffinityforNMDARwhichallowsittoblockthereceptorwithoutnegativelyinfluencingnormalsynapticsignaling [10].”
InfluentialGupta, D. P., Lee, Y., Choe, Y., Kim, K.-T., Song, G. J., & Hwang, S. (2023) · Molecular Brain · doi:10.1186/s13041-022-00986-9 · Cited by 50
“AD may be caused by a combination of many different risk factors [17, 18].”
BackgroundDendrimers in Neurodegenerative Diseases
Pérez‐Carrión, M. D., & Posadas, I. (2023) · Processes · doi:10.3390/pr11020319 · Cited by 50
Attia, M. S., Yahya, A. S., Abdelmonaem, N., & Sabry, S. A. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.01.009 · Cited by 45
“Additional factors involving the usage of cholinergic receptor antagonists (scopolamine) and reduction in glutamate concentration and D -aspartate uptake might lead to the progression of neuronal damage (Breijyeh and Karaman, 2020; Ferreira-Vieira et al., 2016; Monczor, 2005).”
Song, L., Qu, Y. Q., Tang, Y. P., Chen, X., Lo, H. H., Li, Q., Yun, Y. X., Wong, V. K. W., Zhang, R. L., Wang, H. M., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102637 · Cited by 46
Neutrophil biology in injuries and diseases of the central and peripheral nervous systems
Balog, B. M., Sonti, A., & Zigmond, R. E. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102488 · Cited by 51
Albadrani, H. M., Chauhan, P., Ashique, S., Babu, M. A., Iqbal, D., Almutary, A. G., Abomughaid, M. M., Kamal, M., Paiva‐Santos, A. C., Alsaweed, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116376 · Cited by 53
Biji, C. A., Balde, A., & Nazeer, R. A. (2024) · Inflammation Research · doi:10.1007/s00011-024-01893-6 · Cited by 47
“The disease is associated with the accu - mulation of amyloid-beta peptide (Aβ) in specific regions of the brain, such as the medial temporal lobe and neocorti - cal areas, resulting in the development of neuritic plaques and neurofibrillary tangles [ 42 ].”
Influence of human gut microbiome on the healthy and the neurodegenerative aging
Borrego-Ruiz, A., & Borrego, J. J. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112497 · Cited by 47
Kruszka, J., Martyński, J., Szewczyk‐Golec, K., Woźniak, A., & Nuszkiewicz, J. (2025) · Brain Sciences · doi:10.3390/brainsci15050485 · Cited by 47
“Histopathological examination revealed characteristic extracellular amyloid-β (A β ) plaques and intracellular neurofibrillary tangles (NFTs) in the cerebral cortex, along with significant neuronal loss, distinguishing AD from other forms of dementia [2,3].”
Alzheimer’s Disease: From Immune Homeostasis to Neuroinflammatory Condition
Cariddi, L. P., Mauri, M. F., Cosentino, M., Versino, M., & Marino, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113008 · Cited by 47
Tamfu, A. N., Roland, N., Munvera, A. M., Küçükaydın, S., Monde, G., Botezatu, A. V. D., Duru, M. E., & Dinică, R. M. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103675 · Cited by 58
Closest horizons of Hsp70 engagement to manage neurodegeneration
Venediktov, A. A., Bushueva, O. Y., Kudryavtseva, V. A., Kuzmin, E. A., Moiseeva, A. V., Baldycheva, A. V., Meglinski, I. V., & Piavchenko, G. A. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1230436 · Cited by 45
“Despite being debatable, this A β hypothesis of AD is still considered to be generally accepted (Breijyeh and Karaman, 2020).”
He, J., Jin, Y., He, C., Li, Z., Yu, W., Zhou, J., Luo, R., Chen, Q., Wu, Y., Wang, S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1338804 · Cited by 47
“In the face of a globally aging population, AD emerges as a signi fi cant age-related dementia challenge (Breijyeh and Karaman, 2020).”
BackgroundTransplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer’s Disease
Hong, C., Chen, M., Duan, R., Wang, X., Pang, Z., Ge, L., Lü, M., Xie, H., & Liu, Z. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03044-6 · Cited by 45
“To date, no effective treatment has been available to cure AD by repairing damaged neural network [4, 8].”
BackgroundChen, Y., Gu, Y., Xiong, X., Zheng, Y., Liu, X., Wang, W., & Meng, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113467 · Cited by 43
Ertaş, A., Yiğitkan, S., & Orhan, İ. E. (2023) · Pharmaceuticals · doi:10.3390/ph16020171 · Cited by 35
Jain, D., Hasan, N., Zafar, S., Thakur, J., Haider, K., Parvez, S., & Ahmad, F. J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104555 · Cited by 47
Guan, W., & Wang, Q. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154938 · Cited by 46
Novel roles of PIWI proteins and PIWI-interacting RNAs in human health and diseases
Wu, Z., Yu, X., Zhang, S., He, Y., & Guo, W. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01368-x · Cited by 44
“Alzheimer’s disease (AD), the most common form of dementia, is characterized by progressive memory loss and other cognitive abilities [259, 351].”
BackgroundUnveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications
Nelson, V. K., Jha, N. K., Nuli, M. V., Gupta, S. K., Kanna, S., Gahtani, R. M., Hani, U., Singh, A. K., Abomughaid, M. M., Abomughayedh, A. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102224 · Cited by 48
Reich, N., & Hölscher, C. (2024) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2024.101122 · Cited by 45
Comprehensive Overview of Alzheimer’s Disease: Etiological Insights and Degradation Strategies
Singh, M. K., Shin, Y., Ju, S., Han, S., Kim, S. S., & Kang, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136901 · Cited by 49
“Rare variants in APOE3 with mutations in the lipid-binding or lipoprotein receptor-binding regions decrease the risk of AD to a comparable extent as APOE2 [1].”
BackgroundMunteanu, C., Galaction, A., Turnea, M. A., Blendea, C. D., Rotariu, M., & Poştaru, M. (2024) · Antioxidants · doi:10.3390/antiox13091062 · Cited by 49
“Alzheimer’s disease (AD) primarily affects individuals over 65 years old, with the risk doubling approximately every five years after this age threshold [3–6].”
Microbial signatures and therapeutic strategies in neurodegenerative diseases
Rob, M., Yousef, M., Lakshmanan, A. P., Mahboob, A., Terranegra, A., & Châari, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117905 · Cited by 47
Recent Insights in Multi‐Target Drugs in Pharmacology and Medicinal Chemistry
Cemali, S. H., Poyraz, S., Belveren, S., Taş, S., Tamer, M. A., Döndaş, N. Y., Döndaş, H. A., & Sansano, J. M. (2025) · ChemMedChem · doi:10.1002/cmdc.202500447 · Cited by 50
Nanomaterials for Modulating the Aggregation of β-Amyloid Peptides
Huang, Y., Chang, Y. K., Liu, L., & Wang, J. (2021) · Molecules · doi:10.3390/molecules26144301 · Cited by 44
Ferroptosis Mechanisms Involved in Hippocampal-Related Diseases
Wang, X., Wang, Z., Cao, J., Dong, Y., & Chen, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189902 · Cited by 47
“The accumulation of abnormally folded amyloid-β (Aβ) peptides in extracellular plaques and hyperphosphorylated tau proteins in intracellular tangles are two major pathological hallmarks of AD [99].”
BackgroundNavakkode, S., Gaunt, J. R., Pavón, M. V., Bansal, V. A., Abraham, R. P., Chong, Y. S., Ch’ng, T. H., & Sajikumar, S. (2021) · Aging Cell · doi:10.1111/acel.13502 · Cited by 44
Tow, W., Chee, P. Y., Sundralingam, U., & Palanisamy, U. D. (2022) · Nutrients · doi:10.3390/nu14173494 · Cited by 46
“The study postulated the disease was a result of reduced synthesis or increased destruction of acetylcholine [37,73].”
BackgroundTherapeutic potential of ADAM10 modulation in Alzheimer’s disease: a review of the current evidence
Khezri, M. R., Mohebalizadeh, M., & Ghasemnejad‐Berenji, M. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01072-w · Cited by 47
“AD is characterized by aggregation of amyloid β (Aβ)-containing extracellular plaques and tau-containing intracellular neurofibrillary tangles in the neurons [2, 3].”
BackgroundBanerjee, C., Tripathy, D., Kumar, D., & Chakraborty, J. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105831 · Cited by 47
Li, G., Hsu, L., Wu, Y., Bozoki, A., Shih, Y. I., & Yap, P. (2025) · Communications Medicine · doi:10.1038/s43856-025-00736-7 · Cited by 51
“2 – 9 are available in Supplementary Data 2 – 9.”
Asim, A., Jastrzębski, M. K., & Kaczor, A. A. (2025) · Molecules · doi:10.3390/molecules30142975 · Cited by 46
“A deficit in essential amino acids and in nicotinic and muscarinic receptors neurotransmission has also been noted [10,11].”
InfluentialYu, M., Zhang, J., Yu, L., Yang, H., Lu, H., Wei, X., & Xu, J. (2026) · Artificial Intelligence Review · doi:10.1007/s10462-025-11438-w · Cited by 42
“Its pathological hallmarks include senile plaques formed by deposition of β-amyloid plaque deposition and neurofibrillary tangles caused by hyper - phosphorylated tau protein (Breijyeh and Karaman 2020 ).”
Antidepressants in Alzheimer’s Disease: A Focus on the Role of Mirtazapine
Correia, A. S., & Vale, N. (2021) · Pharmaceuticals · doi:10.3390/ph14090930 · Cited by 45
“In turn, the extracellular accumulation of Aβ protein forms the so-called senile plaques, which play a preponderant role in neural function, leading to neurotoxicity and consequent dysfunction of several brain areas, such as the hippocampus, resulting in progressive cognitive decline [1,14].”
BackgroundThe Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease
Mohammad Shehata, I., Masood, W., Nemr, N., Anderson, A., Bhusal, K., Edinoff, A. N., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022) · Neurology International · doi:10.3390/neurolint14020025 · Cited by 41
“Other estimates suggest that the number is around 50 million worldwide and is projected to reach 152 million by 2050 [14].”
BackgroundStructural Insights Support Targeting ASK1 Kinase for Therapeutic Interventions
Obšilová, V., Honzejková, K., & Obšil, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413395 · Cited by 41
“AD is the main source of dementia, primarily affecting people older than 60 years worldwide (reviewed in [60]).”
BackgroundData resources and computational methods for lncRNA-disease association prediction
Sheng, N., Huang, L., Lu, Y., Wang, H., Yang, L., Gao, L., Xie, X., Fu, Y., & Wang, Y. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106527 · Cited by 44
The Latest Advances in the Diagnosis and Treatment of Dementia
Hafiz, R., Alajlani, L., Ali, A., Algarni, G. A., Aljurfi, H., Alammar, O. A. M., Ashqan, M. Y., & Alkhashan, A. Y. (2023) · Cureus · doi:10.7759/cureus.50522 · Cited by 55
Tau‐targeting nanoparticles for treatment of Alzheimer's disease
Pawar, S., Rauf, M. A., Abdelhady, H. G., & Iyer, A. K. (2024) · Exploration · doi:10.1002/exp.20230137 · Cited by 52
Cont, C., Stute, N., Galli, A., Schulte, C. E., Logmin, K., Trenado, C., & Wojtecki, L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.948204 · Cited by 41
Pharmacological mTOR inhibitors in ameliorating Alzheimer’s disease: current review and perspectives
Xie, P.-L., Zheng, M.-Y., Han, R., Chen, W., & Mao, J.-H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1366061 · Cited by 48
“Age represents the primary risk factor for AD, with most patients above 65 years old, although AD has also been associated with other conditions such as head traumas, infections, diabetes, and environmental factors (Breijyeh and Karaman, 2020; Bellenguez et al., 2022).”
BackgroundYoon, J. H., Lee, H., Kwon, D., Lee, D., Lee, S., Cho, E., Kim, J., & Kim, D. (2024) · Brain Communications · doi:10.1093/braincomms/fcae265 · Cited by 46
“8 Moreover, most brain pathologies are not triggered by a single element but are caused by complex molecular mechanisms.”
BackgroundDetka, J., Płachtij, N., Strzelec, M., Manik, A., & Sałat, K. (2024) · Molecules · doi:10.3390/molecules29184354 · Cited by 42
“…inhibitors (lan-abecestat, verubecestat, atabecestat, umibecestat, also known as CNP520) were unsuccess-fully assessed, and the failure of such potential novel therapies was attributed to several issues, including inefficacy, starting therapy too late, and inappropriate drug dose regimens used [1].”
BackgroundInfluentialAktary, N., Jeong, Y., Oh, S., Shin, Y., Sung, Y., Rahman, M., Santiago, L. R., Choi, J., Song, H. G., Nurkolis, F., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1601712 · Cited by 53
“Conventional pharmacological treatments, such as ChEIs and NMDA receptor antagonists, primarily offer symptomatic relief without modifying the disease course (Breijyeh and Karaman, 2020; Peng et al., 2023).”
Meng, S., Wang, B., & Li, W. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03563-7 · Cited by 48
“In AD, the accumulation of β-amyloid (Aβ) may interact with neuronal subcellular organelles, trigger neuronal dysfunction and apoptosis, and lead to memory decline and dementia [1, 4].”
BackgroundAilioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 44
“In most cases, the disease with early onset in younger people is due to an autosomal dominant genetic factor, or to mutations of the genes that are involved in the processing of the amyloid precursor protein (APP), Presenilin-1 (PSEN-1), Presenilin- 2 (PSEN-2) and apolipoprotein E [9,24].”
BackgroundPD-1/PD-L1 pathway: A double-edged sword in periodontitis
Liu, X., Yang, L., & Tan, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114215 · Cited by 43
Wang, Y., Li, Q., Li, X., Zhao, Y., Wang, C., Xue, C., Wang, Y., & Zhang, T. (2023) · Marine Drugs · doi:10.3390/md21070410 · Cited by 41
“Currently, there are about 50 million AD patients worldwide, and this number is expected to double every five years, rising to 152 million by 2050 [3].”
BackgroundLachinov, D., Chakravarty, A., Grechenig, C., Schmidt-Erfurth, U. M., & Bogunović, H. (2023) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2023.3330576 · Cited by 52
“Around 50 million patients suffer from this impairment worldwide, with the projected number of patients effectively doubling every 5 years and reaching 152 million by 2050 [7].”
BackgroundResmi, A. N., Nazeer, S. S., Dhushyandhun, M. E., Paul, W., Chacko, B. P., Menon, R. N., & Jayasree, R. S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00369 · Cited by 39
Drosophila Model for Studying Gut Microbiota in Behaviors and Neurodegenerative Diseases
Chiang, M.-H., Ho, S.-M., Wu, H.-Y., Lin, Y.-C., Tsai, W.-H., Wu, T., Lai, C., & Wu, C. (2022) · Biomedicines · doi:10.3390/biomedicines10030596 · Cited by 44
“Several AD risk factors have been identified, such as aging, genetic background, amyloid precursor protein mutations, environmental factors, and heavy metal exposure [105].”
BackgroundLipid-based nanoparticles and RNA as innovative neuro-therapeutics
Tsakiri, M., Zivko, C., Demetzos, C., & Mahairaki, V. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.900610 · Cited by 41
“Moreover, in many of these conditions such as AD, the only available treatment options are symptomatic and do not address the underlying cause of the disease (Breijyeh and Karaman, 2020).”
BackgroundLi, X., Han, J., Bujaranipalli, S., He, J., Kim, E. Y., Kim, H. Y., Im, J. H., & Cho, W. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114444 · Cited by 39
Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach
Jahan, S., Redhu, N. S., Siddiqui, A. J., Iqbal, D., Khan, J., Banawas, S., Alaidarous, M., Alshehri, B., Mir, S. A., Adnan, M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061123 · Cited by 40
“NMDAR dysfunction can cause central nervous system (CNS) disease in a variety of ways: excessive activation can cause neuronal death, as in stroke and possibly Huntington’s disease, or reduced activity can disrupt the balance of excitation and inhibition in the neural circuitry, affecting CNS functions, as in schizoph…”
BackgroundComprehensive Review of Nutraceuticals against Cognitive Decline Associated with Alzheimer’s Disease
Reza-Zaldívar, E. E., & Jacobo‐Velázquez, D. A. (2023) · ACS Omega · doi:10.1021/acsomega.3c04855 · Cited by 47
Gautam, D., Naik, U. P., Naik, M. U., Yadav, S. K., Chaurasia, R. N., & Dash, D. (2023) · Biomolecules · doi:10.3390/biom13111609 · Cited by 41
“The complexity of AD is heightened by additional environmental risk factors such stress, pollution, and heavy metal exposure [15,32,33].”
BackgroundExosomes isolated from citrus lemon: a promising candidate for the treatment of Alzheimer's disease
Dolma, L., Damodaran, A., Panonnummal, R., & Nair, S. C. (2024) · Therapeutic Delivery · doi:10.1080/20415990.2024.2354119 · Cited by 39
Aborode, A. T., Emmanuel, O. A., Onifade, I. A., Olotu, E., Otorkpa, O. J., Mehmood, M. Q., Abdulai, S. I., Jamiu, A. T., Osinuga, A., Oko, C. I., et al. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2024.100034 · Cited by 42
Mitochondrial-based therapies for neurodegenerative diseases: a review of the current literature
Wadan, A. S., Shaaban, A., El-Sadek, M. Z., Mostafa, S. A., Moshref, A. S., El‐Hussein, A., Ellakwa, D. E., & Mehanny, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04014-0 · Cited by 47
“As our global population ages, these illnesses become increasingly widespread, imposing a significant emotional and financial strain on individuals, caregivers, and healthcare systems (Feigin et al. 2019; Scheltens et al. 2021; Breijyeh and Karaman 2020).”
Non-coding RNAs: The Neuroinflammatory Regulators in Neurodegenerative Diseases
Jiang, H., Zhang, Y., Yue, J., Shi, Y., Xiao, B., Xiao, W., & Luo, Z. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.929290 · Cited by 40
“At present, the treatment of PD and AD are facing similar problems: taking symptomatic drugs cannot reverse the degenerative process, the symptoms of patients still deteriorate gradually with time and the demand for symptomatic drugs tends to increase (123).”
BackgroundImmune Regulatory Functions of Macrophages and Microglia in Central Nervous System Diseases
Poppell, M., Hammel, G., & Ren, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065925 · Cited by 41
Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects
Li, J., Liao, W., Huang, D., Ou, M., Chen, T., Wang, X., Zhao, R., Zhang, L., Mei, L., Liu, J., et al. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215375 · Cited by 38
Jarek, D. J., Mizerka, H., Nuszkiewicz, J., & Szewczyk‐Golec, K. (2024) · Biomedicines · doi:10.3390/biomedicines12040786 · Cited by 43
“The molecular mechanism of AD is determined by the accumulation of both β -amyloid (A β ) in the form of extracellular neuritic plaques and hyperphosphorylated tau protein in the form of intracellular neurofibrillary tangles (NFTs) [27,28].”
BackgroundYekeler, H. B., Güler, E., Beato, P. S., Priya, S., Abobakr, F. K. M., Doğan, M., Üner, B., Kalaskar, D. M., & Çam, M. E. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131841 · Cited by 38
Arroyo-Pacheco, N., Sarmiento-Blanco, S., Vergara-Cadavid, G., Castro-Leones, M., & Contreras‐Puentes, N. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102620 · Cited by 44
Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer’s Diseases
Yang, H., Tan, H., Wen, H., Xin, P., Liu, Y., Deng, Z., Xu, Y., Gao, F., Zhang, L., Ye, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c11966 · Cited by 39
Wan, T., Fu, M., Jiang, Y., Jiang, W., Li, P., & Zhou, S. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03448-1 · Cited by 40
Potential roles of branched-chain amino acids in neurodegeneration
Yoo, H.-S., Shanmugalingam, U., & Smith, P. D. (2022) · Nutrition · doi:10.1016/j.nut.2022.111762 · Cited by 42
Research Progress of Pyroptosis in Alzheimer’s Disease
Xue, W., Cui, D., & Qiu, Y. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.872471 · Cited by 46
Khaliq, F., Mahajani, S. U., Oberhauser, J., & Wakhloo, D. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355982 · Cited by 42
Zhang, Y., Tang, C., He, Y., Zhang, Y., Li, Q., Zhang, T., Zhao, B., Tong, A., Zhong, Q., & Zhong, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117540 · Cited by 36
Traub, J., Otto, M., Sell, R., Göpfert, D., Homola, G. A., Steinacker, P., Oeckl, P., Morbach, C., Frantz, S., Pham, M., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01087-4 · Cited by 38
“Laboratory analysis Non-fasting venous blood samples were collected for routine clinical chemistry investigations at the certified Background Alzheimer’s dementia (AD) is a growing medical and health economic challenge with a rapidly increasing incidence due to aging and already affects approximately 50 million people…”
BackgroundTherapeutics of Alzheimer’s Disease: Recent Developments
Burns, S., Selman, A., Sehar, U., Rawat, P., Reddy, A. P., & Reddy, P. H. (2022) · Antioxidants · doi:10.3390/antiox11122402 · Cited by 40
“Abbreviations AAV—adeno-associated virus; ABP—androgen-binding protein; ABP—Aβ plaques; AD—Alzheimer’s disease; APP—amyloid precursor protein; ATP—adenosine triphosphate; Aβ—amyloid-p; BBB—blood–brain barrier; BDNF—brain-derived neurotrophic factor; CEE—conjugated equine estrogen; CSF—cerebrospinal fluid; DNA—deoxyrib…”
BackgroundInfluentialKhaleghi-Mehr, M., Delshad, A.-A., Shafie-Damavandi, S., & Roghani, M. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01170-1 · Cited by 37
“Although drugs with cholinesterase inhibitory activity have been certified for symptomatic relief of the disease (Breijyeh and Karaman 2020) and recently aducanumab as an amyloid beta-targeted antibody has received FDA approval (Wallin et al.”
BackgroundYe, J., Zeng, A., Pan, D., Zhang, Y., Zhao, J., Chen, Q., & Liu, Y. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3368500 · Cited by 38
“Due to the lack of effective treatment for AD at present, early diagnosis of AD is the only way to inhibit disease progression and improve patient’s quality of life [2].”
BackgroundChen, Y., Lai, M., & Tao, M. (2024) · Medicine · doi:10.1097/md.0000000000037799 · Cited by 52
“[2,38] Hence, the acetylcholinesterase enzyme (AChE), hydrolyzing the ACh, is a breakthrough in the treatment of AD.”
BackgroundMesenchymal Stem Cell-Derived Exosomes as a Neuroregeneration Treatment for Alzheimer’s Disease
Shah, S., Mansour, H. M., Aguilar, T. M., & Lucke-Wold, B. P. (2024) · Biomedicines · doi:10.3390/biomedicines12092113 · Cited by 41
“Elevated levels of A β 42 lead to the formation of toxic amyloid aggregates that damage neurons [26,27].”
BackgroundRole of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier
Cazalla, E., Cuadrado, A., & García‐Yagüe, Á. J. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00599-5 · Cited by 41
“Alzheimer’s Disease (AD) accounts for 60–70% of all dementia cases and is generally characterized by an accumulation of amyloid-β (Aβ) in the form of senile plaques (SPs) and TAU protein in neurofibrillary tangles (NFTs) [192–194].”
Shaik, M. A., Anik, F. I., Hasan, M. M., Chakravarty, S., Ramos, M. D., Rahman, M. A., Ahamed, S. I., & Sakib, N. (2025) · JMIR Aging · doi:10.2196/69175 · Cited by 42
“The main cause of AD is the accumulation of abnormal proteins such as β -amyloid and microtubule-associated tau protein in the brain; the aggregation of these proteins causes synaptic disintegration and neural loss, which characterize AD [3,4].”
Next-Generation Drug Delivery for Neurotherapeutics: The Promise of Stimuli-Triggered Nanocarriers
Boyuklieva, R., Zahariev, N., Simeonov, P., Penkov, D., & Katsarov, P. (2025) · Biomedicines · doi:10.3390/biomedicines13061464 · Cited by 38
“Pichla et al. investigated pH-responsive redox poly(ethylene glycol)-b-poly [4-(2,2,6,6-tetramethylpiperidine-1-oxyl)aminomethylstyrene] NPs (referred to as NRNPs pH) and their effects on the viability of SH-SY5Y cells when treated with 6-OHDA at pH levels of 6.5 and 7.4.”
InfluentialKim, K. Y., Shin, K. Y., & Chang, K.-A. (2021) · Biomolecules · doi:10.3390/biom11070980 · Cited by 35
“NFTs are abnormal filaments of hyperphosphorylated tau proteins that can be twisted around each other in some stages to form paired helical filaments and accumulate in the neural perikaryal cytoplasm, axons, and dendrites, which causes a loss of cytoskeletal microtubules and tubulin-associated proteins [55].”
BackgroundSuttisansanee, U., Thiyajai, P., Chalermchaiwat, P., Wongwathanarat, K., Pruesapan, K., Charoenkiatkul, S., & Temviriyanukul, P. (2021) · Plants · doi:10.3390/plants10081563 · Cited by 36
“Nevertheless, A. sativum seemed to be the least active extract against these NCDs-related enzymes, in which no inhibitory activities against α–glucosidase, acetylcholinesterase (AChE), and BACE-1 were observed.”
BackgroundInfluentialXie, T., Pei, Y., Shan, P., Xiao, Q., Fei, Z., Huang, L., & Wang, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.909222 · Cited by 39
“The main clinical manifestations are memory loss and behavior changes, especially in elderly patients (Tiwari et al., 2019; Breijyeh and Karaman, 2020).”
BackgroundMulti-omic integration via similarity network fusion to detect molecular subtypes of ageing
Yang, M., Matan-Lithwick, S., Wang, Y., De Jager, P. L., Bennett, D. A., & Felsky, D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad110 · Cited by 35
“logical process, Alzheimer’s disease is defined by the abnormal accumulation of neurofibrillary tangles (hyperphosphorylated tau protein), the formation of extracellular dense core plaque deposits (beta-amyloid) and chronic neuroinflammation in the brain.(4) However, there is great inter-individual heterogeneity in th…”
BackgroundElmaaboud, M. A. A., Estfanous, R. S., Atef, A., Kabel, A. M., Alnemari, K. A., Naguib, T. M., Alsufyani, S. E., Darwish, H. W., & Arab, H. H. (2023) · Pharmaceuticals · doi:10.3390/ph16101370 · Cited by 36
“Alzheimer’s disease (AD) is one of the most prevalent forms of neurodegenerative disorders worldwide [1].”
BackgroundTouhtouh, J., Laghmari, M., Benali, T., Aanniz, T., Lemhadri, A., Akhazzane, M., Habbadi, K., Bouyahya, A., Zengin, G., & Hammani, K. (2023) · Biochemical Systematics and Ecology · doi:10.1016/j.bse.2023.104733 · Cited by 37
Wang, C., Wang, J., Zhu, Z., Hu, J., & Lin, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1421076 · Cited by 46
“Nearly 30 sites can be phosphorylated in normal tau proteins, but overphosphorylation causes tau proteins to detach from microtubules and form NFTs (61, 62).”
BackgroundRecent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Anitha, K., Singh, M. K., Kohat, K., Varshini, T. S., Chenchula, S., Padmavathi, R., Amerneni, L. S., Vishnu Vardhan, K., Mythili Bai, K., Chavan, M. R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04384-1 · Cited by 42
Alzheimer’s Disease and Porphyromonas gingivalis: Exploring the Links
Shawkatová, I., Ďurmanová, V., & Javor, J. (2025) · Life · doi:10.3390/life15010096 · Cited by 39
The emerging role of microbiota derived SCFAs in neurodegenerative disorders
Wachamo, S., & Gaultier, A. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101012 · Cited by 44
“AD is the most common form of dementia among older adults and is characterized by a progressive decline in cognitive function (Breijyeh and Karaman, 2020).”
Humanin and Alzheimer's disease: The beginning of a new field
Niikura, T. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.130024 · Cited by 35
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Poliwoda, S., Kaye, R. J., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.37023 · Cited by 43
peng, Y., Chi, R., Liu, G., Tian, W., Zhang, J., & Zhang, R. (2022) · Neural Plasticity · doi:10.1155/2022/1500710 · Cited by 39
“AD is marked by cognitive decline [8] and a progressive decline in independence [9, 10].”
BackgroundYan, Y.-P., Chen, J., & Lu, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315238 · Cited by 38
“Currently, the most widely accepted hypotheses of AD are the cholinergic hypothesis, the amyloid hypothesis, and tau hypothesis [3].”
BackgroundRoles of the cytoskeleton in human diseases
Li, M., Li, P., Wang, Z., Liu, L., Cao, M., Cui, J., Wu, F., & Yang, J. (2023) · Molecular Biology Reports · doi:10.1007/s11033-022-08025-5 · Cited by 39
Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases
Beura, S. K., Dhapola, R., Panigrahi, A. R., Yadav, P., Kumar, R., HariKrishnaReddy, D., & Singh, S. K. (2023) · Medicinal Research Reviews · doi:10.1002/med.21965 · Cited by 40
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.